Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper

A discrete survival and growth mixture model

Thomas F. Northrup, Angela L. Stotts, Charles Green, Jennifer S. Potter, Elise N. Marino, Robrina Walker, Roger D. Weiss, Madhukar Trivedi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: Most patients relapse to opioids within one month of opioid agonist detoxification, making the antecedents and parallel processes of first use critical for investigation. Craving and withdrawal are often studied in relationship to opioid outcomes, and a novel analytic strategy applied to these two phenomena may indicate targeted intervention strategies. Methods: Specifically, this secondary data analysis of the Prescription Opioid Addiction Treatment Study used a discrete-time mixture analysis with time-to-first opioid use (survival) simultaneously predicted by craving and withdrawal growth trajectories. This analysis characterized heterogeneity among prescription opioid-dependent individuals (N. =. 653) into latent classes (i.e., latent class analysis [LCA]) during and after buprenorphine/naloxone stabilization and taper. Results: A 4-latent class solution was selected for overall model fit and clinical parsimony. In order of shortest to longest time-to-first use, the 4 classes were characterized as 1) high craving and withdrawal, 2) intermediate craving and withdrawal, 3) high initial craving with low craving and withdrawal trajectories and 4) a low initial craving with low craving and withdrawal trajectories. Odds ratio calculations showed statistically significant differences in time-to-first use across classes. Conclusions: Generally, participants with lower baseline levels and greater decreases in craving and withdrawal during stabilization combined with slower craving and withdrawal rebound during buprenorphine taper remained opioid-free longer. This exploratory work expanded on the importance of monitoring craving and withdrawal during buprenorphine induction, stabilization, and taper. Future research may allow individually tailored and timely interventions to be developed to extend time-to-first opioid use.

Original languageEnglish (US)
Pages (from-to)20-28
Number of pages9
JournalAddictive Behaviors
Volume41
DOIs
StatePublished - Sep 28 2014

Fingerprint

Buprenorphine
Opioid Analgesics
Outpatients
Stabilization
Survival
Growth
Trajectories
Prescriptions
Detoxification
Craving
Monitoring
Odds Ratio

Keywords

  • Buprenorphine
  • Craving
  • Latent class
  • Opioid
  • Relapse
  • Withdrawal

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Toxicology
  • Medicine (miscellaneous)

Cite this

Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper : A discrete survival and growth mixture model. / Northrup, Thomas F.; Stotts, Angela L.; Green, Charles; Potter, Jennifer S.; Marino, Elise N.; Walker, Robrina; Weiss, Roger D.; Trivedi, Madhukar.

In: Addictive Behaviors, Vol. 41, 28.09.2014, p. 20-28.

Research output: Contribution to journalArticle

Northrup, Thomas F. ; Stotts, Angela L. ; Green, Charles ; Potter, Jennifer S. ; Marino, Elise N. ; Walker, Robrina ; Weiss, Roger D. ; Trivedi, Madhukar. / Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper : A discrete survival and growth mixture model. In: Addictive Behaviors. 2014 ; Vol. 41. pp. 20-28.
@article{08c475e4109243059601ad5544bf141b,
title = "Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: A discrete survival and growth mixture model",
abstract = "Introduction: Most patients relapse to opioids within one month of opioid agonist detoxification, making the antecedents and parallel processes of first use critical for investigation. Craving and withdrawal are often studied in relationship to opioid outcomes, and a novel analytic strategy applied to these two phenomena may indicate targeted intervention strategies. Methods: Specifically, this secondary data analysis of the Prescription Opioid Addiction Treatment Study used a discrete-time mixture analysis with time-to-first opioid use (survival) simultaneously predicted by craving and withdrawal growth trajectories. This analysis characterized heterogeneity among prescription opioid-dependent individuals (N. =. 653) into latent classes (i.e., latent class analysis [LCA]) during and after buprenorphine/naloxone stabilization and taper. Results: A 4-latent class solution was selected for overall model fit and clinical parsimony. In order of shortest to longest time-to-first use, the 4 classes were characterized as 1) high craving and withdrawal, 2) intermediate craving and withdrawal, 3) high initial craving with low craving and withdrawal trajectories and 4) a low initial craving with low craving and withdrawal trajectories. Odds ratio calculations showed statistically significant differences in time-to-first use across classes. Conclusions: Generally, participants with lower baseline levels and greater decreases in craving and withdrawal during stabilization combined with slower craving and withdrawal rebound during buprenorphine taper remained opioid-free longer. This exploratory work expanded on the importance of monitoring craving and withdrawal during buprenorphine induction, stabilization, and taper. Future research may allow individually tailored and timely interventions to be developed to extend time-to-first opioid use.",
keywords = "Buprenorphine, Craving, Latent class, Opioid, Relapse, Withdrawal",
author = "Northrup, {Thomas F.} and Stotts, {Angela L.} and Charles Green and Potter, {Jennifer S.} and Marino, {Elise N.} and Robrina Walker and Weiss, {Roger D.} and Madhukar Trivedi",
year = "2014",
month = "9",
day = "28",
doi = "10.1016/j.addbeh.2014.09.021",
language = "English (US)",
volume = "41",
pages = "20--28",
journal = "Addictive Behaviors",
issn = "0306-4603",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper

T2 - A discrete survival and growth mixture model

AU - Northrup, Thomas F.

AU - Stotts, Angela L.

AU - Green, Charles

AU - Potter, Jennifer S.

AU - Marino, Elise N.

AU - Walker, Robrina

AU - Weiss, Roger D.

AU - Trivedi, Madhukar

PY - 2014/9/28

Y1 - 2014/9/28

N2 - Introduction: Most patients relapse to opioids within one month of opioid agonist detoxification, making the antecedents and parallel processes of first use critical for investigation. Craving and withdrawal are often studied in relationship to opioid outcomes, and a novel analytic strategy applied to these two phenomena may indicate targeted intervention strategies. Methods: Specifically, this secondary data analysis of the Prescription Opioid Addiction Treatment Study used a discrete-time mixture analysis with time-to-first opioid use (survival) simultaneously predicted by craving and withdrawal growth trajectories. This analysis characterized heterogeneity among prescription opioid-dependent individuals (N. =. 653) into latent classes (i.e., latent class analysis [LCA]) during and after buprenorphine/naloxone stabilization and taper. Results: A 4-latent class solution was selected for overall model fit and clinical parsimony. In order of shortest to longest time-to-first use, the 4 classes were characterized as 1) high craving and withdrawal, 2) intermediate craving and withdrawal, 3) high initial craving with low craving and withdrawal trajectories and 4) a low initial craving with low craving and withdrawal trajectories. Odds ratio calculations showed statistically significant differences in time-to-first use across classes. Conclusions: Generally, participants with lower baseline levels and greater decreases in craving and withdrawal during stabilization combined with slower craving and withdrawal rebound during buprenorphine taper remained opioid-free longer. This exploratory work expanded on the importance of monitoring craving and withdrawal during buprenorphine induction, stabilization, and taper. Future research may allow individually tailored and timely interventions to be developed to extend time-to-first opioid use.

AB - Introduction: Most patients relapse to opioids within one month of opioid agonist detoxification, making the antecedents and parallel processes of first use critical for investigation. Craving and withdrawal are often studied in relationship to opioid outcomes, and a novel analytic strategy applied to these two phenomena may indicate targeted intervention strategies. Methods: Specifically, this secondary data analysis of the Prescription Opioid Addiction Treatment Study used a discrete-time mixture analysis with time-to-first opioid use (survival) simultaneously predicted by craving and withdrawal growth trajectories. This analysis characterized heterogeneity among prescription opioid-dependent individuals (N. =. 653) into latent classes (i.e., latent class analysis [LCA]) during and after buprenorphine/naloxone stabilization and taper. Results: A 4-latent class solution was selected for overall model fit and clinical parsimony. In order of shortest to longest time-to-first use, the 4 classes were characterized as 1) high craving and withdrawal, 2) intermediate craving and withdrawal, 3) high initial craving with low craving and withdrawal trajectories and 4) a low initial craving with low craving and withdrawal trajectories. Odds ratio calculations showed statistically significant differences in time-to-first use across classes. Conclusions: Generally, participants with lower baseline levels and greater decreases in craving and withdrawal during stabilization combined with slower craving and withdrawal rebound during buprenorphine taper remained opioid-free longer. This exploratory work expanded on the importance of monitoring craving and withdrawal during buprenorphine induction, stabilization, and taper. Future research may allow individually tailored and timely interventions to be developed to extend time-to-first opioid use.

KW - Buprenorphine

KW - Craving

KW - Latent class

KW - Opioid

KW - Relapse

KW - Withdrawal

UR - http://www.scopus.com/inward/record.url?scp=84907731458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907731458&partnerID=8YFLogxK

U2 - 10.1016/j.addbeh.2014.09.021

DO - 10.1016/j.addbeh.2014.09.021

M3 - Article

VL - 41

SP - 20

EP - 28

JO - Addictive Behaviors

JF - Addictive Behaviors

SN - 0306-4603

ER -